Roche: EMA grants priority review for Huntington's disease

(CercleFinance.com) - The European Medicines Agency (EMA) has granted priority designation to Roche's investigational medicine RG6042 for the treatment of people with Huntington's disease, the Swiss drugmaker said on Friday.


After an encouraging Phase I/IIa trial, Roche plans to initiate a pivotal phase III study to evaluate RG6042 in a larger patient population to further characterise the drug's safety profile and determine whether it can slow the disease's progression in adults.

The "Prime" designation has been implemented by the EMA to provide an accelerated pathway for promising medicines.

Huntington's disease is a rare genetic, progressive condition that causes the nerve cells in the brain to break down, causing personality changes, and difficulty walking and swallowing.

There is no known cure for the disease.

Copyright (c) 2018 CercleFinance.com. All rights reserved.